Няма интернет връзка — показва се запазената версия на страницата.

Arrowhead Pharmac…

USUSD
← Към скрийнъра
US:ARWRLSE:0HI3

Arrowhead Pharmaceuticals Inc (US:ARWR) — Biotechnology: Pharmaceutical Preparations. Брой борси, на които се търгуват акциите на компанията: 2. На тази страница — цена и график, дивиденти, най-големи акционери и история на броя на акциите.

За компанията

Уебсайт
arrowheadpharma.com
Сектор
Health Care · Biotechnology: Pharmaceutical Preparations
Централа
Pasadena, United States
Изпълнителен директор
Christopher R. Anzalone
Служители
711
Основана
2004
Акции в обращение
141.25 млн към 2026-07-30
Свободно търгуеми акции
122.45 млн
Пазарна капитализация
9.22 млрд USD
Инсайдери
3.66%
Институционални инвеститори
85.47%
Отрасъл (SIC)
Pharmaceutical Preparations
ISIN
US04280A1007
LEI
549300O3CSB8T7OZ3D66
FCF
−75.1 млн USD
Дълг
181 млн USD
Печалби и FCF — за 12-те месеца до 30.06.2026 (последният доклад на компанията).
Описание

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.

Борси и тикери

БорсаТикерВалутаЦенаВид
US USA StocksARWR основенUSD60.74 -1.20%обикновени акции
LSE London Stock Exchange0HI3 IOBUSD65.82 +0.00%обикновени акции

Цена за 3 месеца

ден на ръст ден на спадПосочете / докоснете ден — цени на отваряне, затваряне, най-висока и най-ниска

Новини тази седмица

Все още няма новини от сайта на компанията.

реклама

Най-големи притежатели

ПритежателДялАкцииДата на доклада
Blackrock Inc.10.53%14.83 млн2026-06-30
Avoro Capital Advisors L…8.06%11.36 млн2026-06-30
FMR, LLC5.71%8.04 млн2026-06-30
Vanguard Portfolio Manag…4.51%6.35 млн2026-06-30
Vanguard Capital Managem…4.34%6.11 млн2026-06-30
State Street Corporation4.04%5.69 млн2026-06-30
iShares Trust-iShares Co…3.5%4.93 млн2026-08-31
VANGUARD INDEX FUNDS-Van…3.01%4.25 млн2026-06-30
NORGES BANK2.77%3.9 млн2026-06-30
Invesco Ltd.2.76%3.88 млн2026-06-30
ANZALONE CHRISTOPHER RIC…≈2.69%3.79 млн2026-01-02
Geode Capital Management…2.51%3.53 млн2026-06-30
Fred Alger Management, L…2.34%3.3 млн2026-06-30
VANGUARD INDEX FUNDS-Van…2.18%3.07 млн2026-06-30
Fidelity Mt. Vernon Stre…1.81%2.55 млн2026-07-31
Invesco Exchange-Traded…1.27%1.79 млн2026-08-31
VANGUARD INDEX FUNDS-Van…1.26%1.77 млн2026-06-30
VANGUARD INDEX FUNDS-Van…1.15%1.61 млн2026-06-30
SPDR SERIES TRUST-State…1.05%1.48 млн2026-08-31
SPDR S&P MIDCAP 400 ETF…0.73%1.03 млн2026-08-31
iShares Trust-iShares Bi…0.69%968 7382026-07-31
O'BRIEN PATRICK C (Chief…≈0.39%547 4082026-01-06
MYSZKOWSKI KENNETH ALLEN…≈0.32%455 4332025-01-07
HAMILTON JAMES C (Office…≈0.16%226 9582026-04-23
APEL DANIEL JOSEPH (Chie…≈0.12%162 9052026-04-22
GIVEN DOUGLAS BRUCE (Dir…≈0.09%124 1672024-12-17
PERRY MICHAEL S (Directo…≈0.08%111 4592026-08-18
FERRARI MAURO (Director)≈0.05%69 0532025-12-26
WADDILL WILLIAM D (Direc…≈0.04%56 5632025-12-19
LU HONGBO B (Director)≈0.04%52 0122026-05-12